

7 QUICK TIPS FOR INJECTING WITH YOUR BASAGLAR® KWIKPEN®

Always refer to and follow the Consumer Information instructions for dosing and administration that come with your BASAGLAR[®] packaging or the **Instructions for Use for your BASAGLAR[®] Pen**, or call the Eli Lilly Customer Response Centre at 1-888-545-5972. *Follow your healthcare professional's instructions for sanitary injections.*

Fo	ollow your	healthcare professional's instruct	ions for sanitary injections.			
		ou start insulin, you'll need to gr glucose levels of 4.0-7.0 mmol/L	on about dose titration radually adjust your dose to achieve fasting . (or the target your doctor has given you). ot sure what target is right for you.			
		uggested starting dose: nits once daily at bedtime	Increase your dose by 1 unit per day until target is reached			
Ad	apted from the 2	2018 Diabetes Canada Guidelines.	-			
1.	•		en") has the right insulin. Do not use a after the expiration date stamped on the label.			
2.	Î		the seal with an alcohol swab. BASAGLAR® —no particles! Push a new, capped needle on			
3.		 Prime Your Pen Dial 2 units. Tap the cartridge holder to collect air bubbles at the top. Push and hold the dose knob until it stops and count slowly to 5. Insulin should be at the needle tip. If you do not see insulin, repeat the priming steps, but not more than 4 times. 				
4.	Î.	Dial Your Dose Dial the units of BASAGLAR® as recommended by your HCP. If your dose is more than 80 units, you will need more than one injection. Always check the number in the dose window to make sure you have dialed the correct dose.				
5.	FRONT BACK	Pick a Site Change your injection site eac	h time you inject.			
6.	1, 2, 3, 4, 5		e knob in and count slowly to 5 before removing for several seconds. Do not try injecting by vill NOT receive your insulin.			
7.	T	Finish Up Make sure "O" is in the dose w needle in a sharps container.	ndow. Recap, unscrew, and dispose of the used			

Your dosage of BASAGLAR[®] is unique to you and was determined by your healthcare professional. Many factors may affect your usual BASAGLAR[®] dose, including changes in your diet, activity, or work schedule. Talk to your healthcare professional if you see your insulin requirements are changing noticeably.



IMPORTANT SAFETY INFORMATION

BASAGLAR' (insulin glargine) injection is a recombinant human insulin analogue that is a long-acting blood-glucoselowering agent administered subcutaneously (under the skin) once a day. BASAGLAR' is indicated in the treatment of patients over 17 years of age with type 1 or type 2 diabetes who require basal (long-acting) insulin for the control of hyperglycemia (high blood sugar). BASAGLAR' is also indicated in the treatment of pediatric patients (>6 years old) with type 1 diabetes who require basal (long-acting) insulin for the control of hyperglycemia.

BASAGLAR^{*} should NOT be used if you are allergic to this drug or to any ingredient in the formulation or component of the container; if you have diabetic ketoacidosis (DKA); or for intravenous or intramuscular injections.

Before using BASAGLAR^{*} talk to your healthcare professional if you are: planning to have a baby, are pregnant, or are nursing a baby; taking any medication.

- Hypoglycemia (low blood sugar) is the most common adverse effect of insulin, including BASAGLAR.
- Glucose monitoring is recommended for all patients with diabetes.
- Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma, or death.
- Any change of insulin should be made cautiously and only under medical supervision.
- BASAGLAR[®] should not be used for intravenous or intramuscular administration.
- BASAGLAR^{*} must not be mixed with any other insulin or diluted with any other solution because it might not work as intended.
- BASAGLAR^{*} shall not be used if it is not water-clear and colourless or if it has formed a deposit of solid particles on the wall of the cartridge.

Other side effects can occur, including: hyperglycemia (high blood sugar), diabetic ketoacidosis (DKA), allergic reactions to insulin, and skin reactions at the injection site.

If you experience the following serious side effects seek immediate medical attention: severe or continuing hyperglycemia or DKA, or allergic reactions.

In case of drug overdose, contact a healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Always check for the name of the insulin on the carton and the cartridge label when you pick it up from the pharmacy to make sure it is the same as the one your doctor has recommended. Accidental mix-ups between insulin glargine and other insulins, particularly short-acting insulins, have been reported. To avoid medication errors between insulin glargine and other insulins, always check your insulin label before each injection.

About BASAGLAR^{*} cartridges and KwikPens[®]: Carefully follow your healthcare professional's directions on how to use BASAGLAR^{*} cartridges and KwikPens[®] to help avoid contamination and possible infection, and to obtain an accurate dose. DO NOT SHARE INJECTION PENS, CARTRIDGES, OR NEEDLES WITH ANYONE ELSE. To prevent the possible transmission of disease, never share a BASAGLAR^{*} cartridge or pen between patients, even if the needle on the delivery device is changed.

For complete instructions, read and follow the patient information leaflet that comes with your BASAGLAR* packaging.

ly Doctor			Phone
Starting at	dose		
Increase by	unit(s) each	day(s) until you reach	

BASAGLAR and KwikPen are registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.

Lilly